Trimethylation of Histone H3 Lysine 36 by Human Methyltransferase PRDM9 Protein*

Mohammad S. Eram†1, Susan P. Bustos†1, Evelyne Lima-Fernandes†2, Alena Siarheyeva‡, Guillermo Senisterra‡, Taranee Hajian‡, Irene Chau‡, Shili Duan‡, Hong Wu‡, Ludmila Dombrovski‡, Matthieu Schapira*, Cheryl H. Arrowsmith‡3, and Masoud Vedadi‡4

From the Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, the Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario MSS 1A8, and the Ontario Cancer Institute and Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 2M9, Canada

Background: Histone methyltransferase PRDM9 marks recombination hot spots and is implicated in sterility and cancers. Results: We identified histone H3K36 as a new methylation mark for PRDM9. Conclusion: PRDM9 is a highly active histone methyltransferase that trimethylates H3K4 and H3K36. Significance: Discovering PRDM9 as a H3K36 methyltransferase could lead to identifying the roles that PRDM9 may play in human fertility and susceptibility to cancer.

PRDM9 (PR domain-containing protein 9) is a meiosis-specific protein that trimethylates H3K4 and controls the activation of recombination hot spots. It is an essential enzyme in the progression of early meiotic prophase. Disruption of the PRDM9 gene results in sterility in mice. In human, several PRDM9 SNPs have been implicated in sterility as well. Here we report on kinetic studies of H3K4 methylation by PRDM9 in vitro indicating that PRDM9 is a highly active histone methyltransferase catalyzing mono-, di-, and trimethylation of the H3K4 mark. Screening for other potential histone marks, we identified H3K36 as a second histone residue that could also be mono-, di-, and trimethylated by PRDM9 as efficiently as H3K4. Overexpression of PRDM9 in HEK293 cells also resulted in a significant increase in trimethylated H3K36 and H3K4 further confirming our in vitro observations. Our findings indicate that PRDM9 may play critical roles through H3K36 trimethylation in cells.
domain of PRDM2, PRDM3, PRDM6, PRDM8, PRDM9, and PRDM16 (24–29). Some PRDMs act as tumor suppressors (e.g., PRDM1, -2, -5, and -12) and others are oncogenic (e.g., PRDM3, -13, -14, and -16) (reviewed by Hohenauer and Moore (22)).

PRDM9 is the only member of the PR domain family whose expression is restricted to germ cells entering meiotic prophase (28). In addition to its PR domain, the protein contains a Krüppel-associated box domain (30) and anywhere from 8 to 18 C2H2 zinc finger repeats (31). The zinc finger domain of the main PRDM9 allele has been shown to bind to a 13-mer recombination hot spot motif on DNA (32, 33). Hot spot motifs are sites of DNA double strand breaks localized to 1–2-kb regions of the genome where homologous recombination takes place during meiosis (34). Trimethylation of H3K4 is a mark for the initiation of recombination in yeast and mice (35–37). PRDM9 has been shown to catalyze the trimethylation of H3K4, consistent with previous reports. We also report that H3K36 is a novel substrate for PRDM9.

Targeted disruption of PRDM9 in mice causes sterility in both sexes as a result of impaired double strand break repair, deficient pairing of homologous chromosomes, and deficient sex body formation (28). In human, two SNPs, C614T in exon 6 and T1086C in exon 9, in PRDM9 were found to occur more frequently in Japanese patients with azoospermia caused by meiotic arrest than in the healthy control group (40). However, there was no difference detected in the methylation activity in vitro between normal PRDM9 and T1086C PRDM9, which caused a Tyr to His missense mutation. Three additional SNPs were found in another group of sterile male patients: two exonic SNPs, G17353T (G433V) and C18109G (T685R), and an intronic SNP, G15549T (41). These SNPs were identified in patients with azoospermia, but not in fertile subjects. PRDM9 is also recurrently mutated (11%) in head and neck squamous cell carcinoma (42).

PRDM9 has been identified as a meiosis-specific cancer/testis gene (43). These genes encode cancer/testis antigens that are a group of cancer-specific biomarkers expressed in the testes of healthy adults that can also be activated in cancers. PRDM9 protein has been detected in the human testicular embryonic carcinoma cell line NTERA-2 and could potentially be used as an antigenic target in clinical applications. Another study linking PRDM9 with cancer found that an excess of rare alleles were found in children affected by B-cell precursor acute lymphoblastic leukemia (B-ALL) and their parents (44).

Here we report on substrate specificity and kinetic characterization of PRDM9. Our results indicate that PRDM9 is a highly active histone methyltransferase that mono-, di-, and trimethylates H3K4, consistent with previous reports. We also report that H3K36 is a novel substrate for PRDM9.

**EXPERIMENTAL PROCEDURES**

**Expression and Purification of PRDM9**—The wild-type PRDM9 gene (amino acids 195–385) was amplified by PCR and subcloned into the pET28a-MHL vector (GenBankTM EF456735). The protein was overexpressed in E. coli BL21(DE3)pRARE2-V2R cells (SGC Toronto) by the addition of 1 mM isopropyl 1-thio-d-galactopyranoside and incubated overnight at 15 °C. Harvested cells were re-suspended in 20 mM Tris–HCl buffer, pH 7.5, with 500 mM NaCl, 5 mM imidazole, and 5% glycerol and flash-frozen in the presence of protease inhibitor (0.1 mM PMSF). The cells were thawed and lysed chemically with 0.5% CHAPS in the presence of 3 mM 2-mercaptoethanol followed by sonication for 10 min on ice at a frequency of 8.5 with 10 s on and off. The crude extract was clarified by high-speed centrifugation (16,000 × g for 1 h). The cleared lysate was loaded onto a Hi-Trap, 5-ml Ni-Chelating HP column using the AKTA system. The column was washed with wash buffer (20 mM Tris–HCl, pH 7.5, 500 mM NaCl, 5% glycerol, and 30 mM imidazole) and the His-tagged PRDM9 protein was eluted in 20 mM Tris–HCl buffer, pH 7.5, 500 mM NaCl, 5% glycerol, and 250 mM imidazole.

Following addition of 3 mM 2-mercaptoethanol, the eluate was loaded onto a Superdex 200 26/60 column equilibrated with 20 mM Tris–HCl, pH 7.5, and 150 mM NaCl. The His tag was cleaved overnight at 4 °C with tobacco etch virus protease. The NaCl in the buffer containing cut protein was diluted to 50 mM prior to injection onto a Source30Q (GE Healthcare Life Sciences) anion exchange column, which was pre-equilibrated with 3 column volumes of 20 mM Tris–HCl buffer, pH 8.0. The protein was eluted by addition of a salt gradient created by 3 column volumes of 20 mM Tris–HCl buffer, pH 7.5, containing 1 M NaCl and 20 mM Tris–HCl buffer, pH 8.0. The pure PRDM9 eluted at 150 and 250 mM NaCl. Fractions with higher than 95% purity based on SDS-PAGE and Coomassie Blue staining were pooled, followed by addition of 2-mercaptoethanol to 3 mM. Pooled fractions were concentrated, flash-frozen, and stored at −80 °C.

**Nucleosome Preparation**—Recombinant nucleosome with wild-type histone H3 (WT) and truncated histone H3 (ΔH3; missing the first 11 residues) were reconstituted as previously described (45).

**PRDM9 Assay for Substrate Specificity Determination**—A radioactivity-based assay was used to determine histone peptide substrate specificity of PRDM9. In this assay [3H]AdoMet (PerkinElmer Life Sciences; catalog number NET1552V250UC) was used as a methyl donor to methylate biotinylated histone peptide substrates. Reaction mixtures contained 10 μM biotinylated peptide and 200 μM AdoMet (4 μM [3H]AdoMet plus 196 μM cold AdoMet) in 10 mM Tris–HCl buffer, pH 8.5, with 0.01% Triton X-100 and 10 mM DTT in a final volume of 20 μl. The reaction was started by adding PRDM9 (final concentration of 1 nM). Samples were incubated for 30 min at 23 °C and the reaction was quenched by addition of 20 μl of 7.5 mM guanidinium hydrochloride followed by addition of 160 μl of 20 mM Tris–HCl buffer, pH 8.0. Samples were added to wells of a streptavidin/scintillant-coated microplate (FlashPlate® PLUS; PerkinElmer Life Sciences). Biotinylated peptides would be captured in each well through their interaction with streptavidin, thereby bringing any incorporated [3H]methyl in proximity of scintillant. The amount of methylated peptide was quantified by tracing the radioactivity (cpm) as measured by the TopCount NXT™ Microplate Scintillation and Luminescence Counter (PerkinElmer Life Sciences).
Assay Optimization—The radioactivity-based assay described above was used to determine the best assay conditions for the PRDM9 methylation reaction. For the pH titration, the reaction mixture contained 10 μM biotinylated peptide and 40 μM AdoMet (2.5 μM [3H]AdoMet plus 37.5 μM cold AdoMet) in 20 mM Bis-tris propane buffer, pH 6.0–9.5, in a final volume of 20 μl. For the NaCl, DMSO, Triton X-100, DTT, and Tris(2-carboxyethyl)phosphine (TCEP) titrations, the reaction mixture contained 10 μM biotinylated peptide and 40 μM AdoMet (2.5 μM [3H]AdoMet plus 37.5 μM cold AdoMet) in 10 mM Tris-Cl, pH 8.5, in a final volume of 20 μl. The reactions were started by adding 100 nM PRDM9. Samples were incubated for 1 h at 23 °C and reactions were quenched by addition of 100 μl of 20% TCA, and allowed to dry, followed by addition of 70 μl of Microcount-O solution (PerkinElmer Life Sciences) to each well. The methylation was quantified by tracing the radioactivity (cpm) as measured by a TopCount reader from PerkinElmer.

Screening PRDM9 against a Known Histone Methyltransferase Inhibitor Library—The Z-factor was determined to ensure the optimized assay was amenable to high-throughput screening in a 384-well format (46). For this determination, 1 nM PRDM9 was screened with H3K36me2 peptide and AdoMet equal to their K_m values (2.5 and 62 μM, respectively). PRDM9 was then screened against a small library of known histone methyltransferase inhibitors using H3K36me2 as substrate under optimized assay conditions. In this assay, 1 nM PRDM9 was incubated with 2.5 μM H3K36me2 peptide, 62 μM AdoMet in a reaction buffer (10 mM Tris-Cl, pH 8.5, 10 mM DTT, 0.01% Triton X-100) along with compounds ranging in concentrations from 0 to 100 μM, with a final DMSO concentration of 1%. Reactions were incubated at 23 °C for 30 min. The IC_{50} value was determined for suramin using SigmaPlot.

Mass Spectrometry Analysis—Mass spectrometry analysis was performed to confirm that PRDM9 is capable of methylating un-, mono-, and dimethylated Lys-36 on the H3-(21–44) peptide. The reactions (40 μl final volume) contained 0.5 mM of each corresponding peptide, 1 μM PRDM9 and 1 mM AdoMet. The reactions were incubated at 24 °C for 5 h, quenched by addition of 110 μl of 0.5% formic acid, and immediately frozen on dry ice. For each reaction a blank was prepared by omitting the enzyme (PRDM9) from the reaction mixture. The samples were analyzed by an Agilent LC/MSD Time-of-Flight (TOF) mass spectrometer (Agilent Technologies, Santa Clara, CA) equipped with an electrospray ion source. To separate the peptide from the protein and remove buffer and salt, the samples were passed through a POROSHELL 300SB-C3 column using a 5%–95% acetonitrile:water gradient.

Isothermal Titration Calorimetry (ITC)—Purified PRMD9 was dialyzed overnight in 20 mM Tris-Cl buffer, pH 8.5. Histone peptides or AdoMet at 1 mM in dialysis buffer were injected into the sample cell containing ~1.4 ml of 30 or 50 μM PRMD9, respectively. ITC titrations were performed on a VP-ITC Micro Calorimeter from GE Healthcare at 25 °C by using 10-μl injections with a total of 25 injections. Data were fitted with a one-binding site model using Microcal Origin software.

Transfection and Immunoblotting of PRDM9 in Cells—A FLAG-tagged control vector or FLAG-tagged PRDM9 construct were transfected into HEK293 cells using GeneJuice (Novagen). Transfected cells were serum-deprived prior to lysis in 50 mM Tris-Cl, 400 mM NaCl, 1 mM EDTA, 0.1% SDS, and 1% Triton X-100 supplemented with protease inhibitors. 30 μg of total cell lysate were processed for Western blotting and immunoblotted using specific antibodies to monitor the levels of H3K36me1 (Abcam, ab9048), H3K36me2 (Cell Signaling Technology, 2901), H3K36me3 (Cell Signaling Technology, number 9763), H3K4me1 (Cell Signaling Technology, 9723), H3K4me2 (Abcam, ab32356), H3K4me3 (Cell Signaling Technology, number 97275), and total H3 (Abcam, ab10799). The transfection efficiency of FLAG-PRDM9 was controlled by
Preliminarily, we screened different soluble constructs of coated membranes and scintillation proximity assay plates. Nylation peptide substrates was monitored using streptavidin-developed and optimized a radioactivity-based assay. In this study, we fully characterized to determine kinetic parameters for PRDM9 activity, we further investigated its substrate specificity. To further investigate its substrate specificity, we fully characterized. To further investigate its substrate specificity, we used an anti-FLAG antibody (FLAG M2 monoclonal, Sigma). Membrane bands were visualized using LiCor IRDye, 680RD anti-rabbit and 800CW anti-mouse secondary antibodies.

**RESULTS**

Although PRDM9 has been reported to trimethylate H3K4 in vitro and in vivo (28), its methyltransferase activity has not been fully characterized. To further investigate its substrate specificity and determine kinetic parameters for PRDM9 activity, we developed and optimized a radioactivity-based assay. In this assay the transfer of methyl groups from [3H]AdoMet to biotinylated peptide substrates was monitored using streptavidin-coated membranes and scintillation proximity assay plates. Preliminarily, we screened different soluble constructs of PRDM9 using H3-(1–25) peptide (first 25 residues of histone H3) and identified an active PR domain-containing construct corresponding to residues 195 to 385.

To determine the substrate specificity of PRDM9 a collection of peptides including two additional H3 peptides (H3-(19–33) and H3-(21–44)), as well as a peptide corresponding to the first 24 residues of histone H4 (H4(1–24)) were also tested (Fig. 1). In this screen, peptides with different methylation states of H3K4, H3K9, H3K27, H3K36, and H4K20 as well as K4A, K4AK9A, and K36A mutations were tested. PRDM9 was active with unmodified H3-(1–25) peptide, as well as with the mono- and dimethylated lysine 4 H3-(1–25) peptides (H3K4me0, H3K4me1, and H3K4me2, respectively). PRDM9 was not active with trimethylated H3K4 indicating that Lys-4 was the methylation mark for PRDM9 and the enzyme had no other methylation target on this peptide (Fig. 1). No activity was observed using K4A, K4AK9Ame1, K4AK9Ame2, K4AK9Ame3, and K4AK9A mutants of H3-(1–25) peptide as substrates, further confirming our conclusion that was consistent with previous reports (28). No activity was detected with the H3-(19–33) peptide with various Lys-27 methylation states. Similarly, PRDM9 was not active with the H4(1–24) peptide with various Lys-20 methylation states. Interestingly, PRDM9 was active with H3-(21–44) peptide with un-, mono-, and dimethylated Lys-36 as substrates, but not when Lys-36 was trimethylated or mutated to alanine (H3K36A) suggesting that Lys-36 may be a new methylation mark for PRDM9 (Fig. 1). We further confirmed the production of mono-, di-, and trimethylated H3K36 by PRDM9 using mass spectrometry (Fig. 2). Taken together, these results indicate the ability of PRDM9 to mono-, di-, and trimethylate residue H3K4 and H3K36 in vitro.

**Assay Optimization**—PRDM9 activity was further characterized with respect to pH, salt (NaCl), reducing agents (DTT and TCEP) and additives (DMSO and Triton X-100). The enzyme showed maximum activity at pH 8.5 (Fig. 3a) in 20 mM Bis-tris propane buffer using H3-(1–25) as a substrate. Experiments were then repeated at pH 8.5 in various concentrations of Tris-HCl, Bis-tris propane, and Bicine buffers, and no significant difference was observed between different buffers (data not shown). All follow-up experiments were then performed using Tris-HCl buffer at pH 8.5.

The ionic strength of the buffer had a dramatic effect on PRDM9 activity with a sharp decrease in activity with increasing NaCl concentrations (Fig. 3b). Enzyme activity was abolished at NaCl concentrations above 125 mM. This negative effect of salt on enzyme activity might be due to interference with electrostatic interactions between the enzyme and its basic peptide substrate.

PRDM9 maintained high levels of activity at all concentrations of DMSO with maximum activity observed at 0.16% (Fig. 3c). The presence of Triton X-100 at concentrations as low as 0.004% dramatically improved the signal to noise ratio; Triton X-100 concentration was kept at 0.01% in all assays. Higher concentrations of Triton X-100 up to 0.25% did not further increase the activity (Fig. 3d).

The effect of reducing agents DTT and TCEP were also examined. Addition of DTT caused an increase in enzyme activity that reached the maximal effect at 10 mM, and was maintained at higher concentrations of DTT (Fig. 3e). Addition
of TCEP on the other hand resulted in maximal enzyme activity at 0.6 mM, followed by a sharp decrease in activity at increasing TCEP concentrations (Fig. 3f). Considering these observations we subsequently used the following assay condition for all kinetic experiments: 10 mM Tris-HCl, pH 8.5, 0.01% Triton X-100, and 10 mM DTT.
Kinetic Parameter Determination—Kinetic parameters were determined with H3-(1–25) peptide with un-, mono-, and dimethylated Lys-4 as well as H3-(21–44) with un-, mono-, and dimethylated Lys-36 as substrates as described under “Experimental Procedures” (Table 1). As expected, PRDM9 was inactive with trimethylated Lys-4 and Lys-36 peptides. The \( K_m \) values for the unmodified H3-(1–25) peptide (H3K4me0) and H3K4me1 were the same (1 \( \pm \) 0.2 \( \mu M \); Table 1, Fig. 4a). The \( K_m \)
value for the H3K4me2 peptide was slightly higher (3 ± 1 μM). The $K_m$ values for AdoMet were also similar with H3K4me0, H3K4me1, and H3K4me2 peptides (120 ± 5 μM, 170 ± 30 μM and 140 ± 9 μM, respectively; Table 1 and Fig. 4b). Although catalytic efficiency ($k_{cat}/K_m$) of PRDM9 is slightly higher (~3 times) for H3K4me0 than for H3K4me2, it efficiently mono-, di-, and trimethylates H3K4. With $k_{cat}$ values as high as 19,000 ± 1,200 h$^{-1}$ under these assay conditions, PRDM9 appears to be the most active histone methyltransferase known to date (Table 1) (48, 49).

$K_m$ values for H3K36me0, H3K36me1, and H3K36me2 were also close (1.5 ± 0.2, 2.4 ± 0.4, and 2.5 ± 0.3 μM, respectively; Table 1 and Fig. 4e). The enzyme was highly active with H3K36me0, H3K36me1, and H3K36me2 peptides as substrate ($k_{cat}$ of 7,500 ± 420 h$^{-1}$, 5,000 ± 700 h$^{-1}$, and 19,000 ± 500 h$^{-1}$, respectively). The $k_{cat}$ value for the reaction with H3K36me2 peptide is significantly higher than that of the H3K36me0 and H3K36me1 peptides. Dimethylated H3K36 appears to be a better substrate for PRDM9. The $K_m$ value for AdoMet was also determined in reactions with H3K36me0, H3K36me1, and H3K36me2 peptides as substrate (87 ± 9, 130 ± 32, and 62 ± 3 μM, respectively; Fig. 4d, Table 1). The optimized assay was amenable to screening in a 384-well format with a Z-factor (46) of 0.82 (Fig. 5a) and was used to screen a small library of known histone methyltransferase inhibitors. We found that suramin inhibits PRDM9 activity with an IC$_{50}$ value of 4.1 ± 0.1 μM (Fig. 5b).

Although we were able to detect the activity (~16,000 cpm) of PRDM9 with human nucleosome (13.5 μM) extracted from HEK293 cells at a high concentration of enzyme (4 μM), we were not able to reach substrate saturation and the level of activity was too low for full kinetic studies. A low level of activity was also observed with recombinant nucleosome as substrate, making further studies on the nucleosome very challenging. However, high levels of activity were observed with the H3-H4 tetramer as a substrate ($k_{cat}$: 4100 ± 320 h$^{-1}$) (Table 1, Fig. 4, e and f). We also truncated the first 11 residues of histone H3 (eliminating H3K4) and reconstituted the H3-H4 tetramer. Truncated H3-H4 tetramer was also a good substrate for PRDM9 ($k_{cat}$: 4,300 ± 300 h$^{-1}$) despite deletion of H3K4, further supporting the H3K36 methylation (Table 1, Fig. 4, e and f). PRDM9 (4 μM) was also active (~11,000 cpm) with nucleosomes reconstituted using truncated H3 (1.6 μM). Under the same conditions, PRDM9 was more active (~38,000 cpm) with wild-type recombinant nucleosome (Fig. 6a). We further confirmed H3K36 methylation on truncated H3 nucleosome by immunoblotting using H3K36me3 antibody, and using H3K4me3 antibody as a control (Fig. 6b and c). Altogether, our data clearly confirms H3K36 methylation by PRDM9.

**Substrate Binding Studies**—Binding affinities of peptide substrates and AdoMet were determined using ITC as described under "Experimental Procedures" (Fig. 7). Consistent with an observed decrease in activity in the presence of high salt (Fig. 3b), very weak peptide binding was observed when performing the ITC experiments in buffers with NaCl such as PBS buffer. Using 20 mM Tris-HCl pH 8.5 buffer, which was similar to the enzyme assay conditions, appeared to be the optimum buffer condition for ITC experiments as well. The difference in $K_D$ values for un-, mono-, and dimethylated Lys-4 and Lys-36 peptides were not significant (ranging from 3.6 to 5.8 μM). However, $K_D$ values for H3K4me3 and H3K36me3 peptides (12 and 9.6 μM, respectively) were significantly higher (Fig. 7, Table 1). The $K_D$ value for AdoMet was 18.6 μM.

**Cell-based Assays**—To investigate the H3K4 and H3K36 methylation activity of PRDM9 in cells, a FLAG-tagged PRDM9 plasmid was transfected into HEK293 cells. H3K4 and H3K36 levels of methylation were monitored by immunoblotting using specific antibodies for methylation states of each mark as specified under "Experimental Procedures" (Fig. 8). The immunoblot quantifications showed a significant increase in trimethylation of H3K4 and H3K36 in cells overexpressing PRDM9, but not mono- or dimethylation of either mark (Fig. 8c). The cell-based data indicate that PRDM9 is capable of trimethylating H3K36 in HEK293 cells.

**H3K36me2 Peptide Docking**—To better understand the structural determinants for H3K4/H3K36 dual specificity, we docked the H3K36me2 peptide GV/Kmeme2(36)KPH to PRDM9 (Fig. 9). Hydrogen bonds engaged with the backbone of the histone peptide observed in the PRDM9-H3K4me2 crystal
structure (PDB code 4C1Q) were conserved in the H3K36me2 complex. H3V35 and H3P38 side chains favorably exploit hydrophobic cavities occupied by H3T3 and H3T6, respectively, in the H3K4me2 complex. Interactions formed with the aliphatic side chain of H3R2 are lost, but H3K37 forms an additional electrostatic interaction with Glu-360. In summary, the model reveals how the substrate-binding groove of PRDM9 has acquired structural features that can accommodate two distinct histone sites.

**DISCUSSION**

PRDM9 is a PR domain-containing protein with multiple zinc fingers that catalyze trimethylation of H3K4 (28). It is a meiosis-specific protein that has been reported to control activation of the short highly recombinogenic segments called recombination hot spots (50). The H3K4me3 mark is often associated with transcriptional activation (51, 52) and DNA repair (53). This methyl mark is also associated with recombination hot spot initiation in yeast and mice (35, 36) where double strand breaks occur prior to crossover events. However, H3K4me3 marks associated with hot spots are distinct from those at transcription start sites (37). It was reported that 87% of double strand break hot spots in mice overlap with testis-specific H3K4me3 marks (37). PRDM9 binds in vitro to a 13-mer DNA sequence enriched in human hot spots (32, 33) where it initiates recombination by its H3K4 trimethylation activity.

Disruption of PRDM9 expression in mice caused sterility (28) and addition of PRDM9 via baculovirus to sterile mouse hybrids rescued the sterile phenotype (54). In human, a handful of PRDM9 SNPs have been shown to be associated with azoospermia and sterility as well (40, 41). The expression of PRDM9 in male germ cells and its role in the progression of meiosis make PRDM9 a candidate target for pharmacologic compounds that may work as non-hormonal, reversible male contraceptives. Recently, PRDM9 variability in humans has been implicated in genome instability and having a potential role in the risk of acquiring genome rearrangements associated with childhood leukemogenesis (44). PRDM9 has a role in genetic diversity and proper progression of meiosis, and a possible increase in risk for a variety of diseases upon change in its activity (31, 33, 44). This raises the question of whether or not variability of PRDM9 and change in its level of activity may contribute to an increased risk for other rearrangement-associated diseases.

Although PRDM9 H3K4 methyltransferase activity has been previously reported (28), to our knowledge its activity and substrate specificity have not been fully characterized. Our kinetic characterization of the PRDM9 H3K4 methyltransferase activity revealed that PRDM9 is one of the most active histone methyltransferase inhibitors and suramin was identified as an inhibitor with an IC50 value of 4.1 ± 0.1 μM. Experiments were performed in triplicate as described under “Experimental Procedures.”
tively. Our binding data also indicated tight H3K4 peptide binding (low micromolar). Previously, Hayashi et al. (28) reported that GST-PRDM9 specifically catalyzed methylation of native calf thymus histone H3 but not recombinant GST-fused full-length H3, even when the GST tag was removed from the substrate. They also observed only trimethylation when peptides were used as substrates and in cells. Very recently PRDM9 was reported to also mono- and dimethylate H3K4 in addition to catalyzing the H3K4 trimethylation (55). Using un-, mono-, and dimethylated peptides as substrate, we did observe, quantify, and characterize the ability of PRDM9 to mono-, di-, and trimethylate H3K4 and H3K36, a novel mark for PRDM9. Binding of PRDM9 to a histone H3-(26–45) peptide on a peptide array was also recently reported that implicated H3K36 as a possible methylation site (55). To further confirm the H3K4/H3K36 monomethylation by PRDM9, we used recombinantly reconstituted H3-H4 tetramer as substrate. PRDM9 indeed methylated H3-H4 tetramer indicating that PRDM9 is capable of catalyzing the monomethylation of its substrates. As PRDM9 di- and trimethylates the monomethylated product very efficiently, it would not be unexpected that the marks would mainly be found in the trimethylated state in cells as previously reported (28) and observed in HEK293 cells.

FIGURE 7. Assessing interactions of PRDM9 with substrates. Binding of H3-(1–25) and H3-(21–44) peptides with various H3K4 and H3K36 methylation states was monitored by ITC as described under “Experimental Procedures.” Peptide substrates and their corresponding $K_D$ values from a single run are indicated on the plots. Experiments were performed in duplicate. Mean $K_D$ values are listed in Table 1.

FIGURE 8. Trimethylation of H3K4 and H3K36 by PRDM9 in cells. Trimethylation of H3K36 (a) and H3K4 (b) in HEK293 cells transfected with control and PRDM9 plasmids was monitored by Western immunoblotting. c, blot quantifications indicate significant H3K4 and H3K36 trimethylation in samples from cells overexpressing PRDM9. Methylation levels of Lys-4 and Lys-36 were quantified and normalized to their respective total H3 levels. FLAG-PRDM9-transfected samples were normalized to samples transfected with FLAG Control vector. IB, immunoblot; CTL, control.
When screening for other possible PRDM9 substrates, we also discovered H3K36 as a novel target residue for PRDM9 methylation using peptide substrates. Methylation of the H3-H4 tetramer and nucleosome when H3 was N terminally truncated further supported H3K36 methylation by PRDM9. H3K36 methylation on truncated nucleosome was further confirmed by immunoblotting. Interestingly, it catalyzed mono-, di-, and trimethylation of H3K36 in vitro with levels comparable with H3K4 methylation. Importantly, we showed that overexpression of PRDM9 in HEK293 cells resulted in a significant increase in H3K36 trimethylation as well as H3K4 trimethylation confirming our in vitro data.

The H3K36me3 mark is found on expressed exons, versus introns, which supports its involvement with transcriptional elongation and splicing (56). Additionally, H3K36me3 regulates DNA mismatch repair through its recruitment of the PWWP domain of MSH6 (57). SETD2, a protein that behaves like a tumor suppressor gene in breast cancer (58) and clear cell renal cell carcinoma (59), also trimethylates H3K36 (13). SETD2 transcripts are found in several human tissues, including testis (60), and the gene was also found to be significantly expressed in the testis compared with 10 other human tissues (60), and the gene was also found to be significantly expressed in the testis compared with 10 other human tissues (60), and the gene was also found to be significantly expressed in the testis compared with 10 other human tissues (60). Although we observed an increase in trimethylation of H3K36 upon overexpression of PRDM9 in HEK293 cells, further studies are needed to show PRDM9-dependent H3K36 trimethylation during meiosis and to clarify its effect and physiological relevance.

CONCLUSION

We have found that PRDM9 is able to trimethylate H3K36 in vitro and in HEK293 cells. The physiological significance of this reaction is not yet known. We also found that PRDM9 was able to mono- and dimethylate H3K4 in vitro, and we confirmed earlier reports of its ability to trimethylate H3K4 in vitro and in HEK293 cells. The restrictive expression of PRDM9 in testis and its association with sterility make this protein a desirable target for male contraceptive design. Compound screens will isolate potential PRDM9 inhibitors to this end.

ACKNOWLEDGMENTS—We thank Dr. Jan Kadlec for sharing the crystal structure of the PRDM9 SET domain in complex with the H3K4me2 peptide and AdoHcy (PDB code 4C1Q) prior to release. We also thank Dr. Lilia Kaustov for providing recombinant human nucleosome.

REFERENCES

1. Kouzarides, T. (2007) Chromatin modifications and their function. Cell 128, 693–705
2. Murray, K. (1964) The occurrence of e-N-methyl lysine in histones. Biochemistry 3, 10–15
3. Byvoet, P., Shepherd, G. R., Hardin, J. M., and Noland, B. J. (1972) The distribution and turnover of labeled methyl groups in histone fractions of cultured mammalian cells. Arch. Biochem. Biophys. 148, 558–567
4. Paik, W. K., and Kim, S. (1967) e-N-Dimethyllysine in histones. Biochem. Biophys. Res. Commun. 27, 479–483
5. Hempel, K., Lange, H. W., and Birkofer, L. (1968) e-N-Trimethyllysine, a new amino acid in histones. Naturwissenschaften 55, 37
6. Borun, T. W., Pearson, D., and Paik, W. K. (1972) Studies of histone methylation during the HeLa S-3 cell cycle. J. Biol. Chem. 247, 4288–4298
7. Greer, E. L., and Shi, Y. (2012) Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 13, 343–357
8. Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., and Patel, D. J. (2007) How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat. Struct. Mol. Biol. 14, 1025–1040
9. Xiao, B., Jing, C., Wilson, J. R., Walker, P. A., Vasisht, N., Kelly, G., Howell, S., Taylor, I. A., Blackburn, G. M., and Gamblin, S. J. (2003) Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature 421, 652–656
10. Patel, A., Dharmarajan, V., Vought, V. E., and Cosgrove, M. S. (2009) On the mechanism of multiple lysine methylation by the human mixed line-age leukemia protein-1 (MLL1) core complex. J. Biol. Chem. 284, 24242–24256
11. Li, Y., Trojer, P., Xu, C. F., Cheung, P., Kuo, A., Drury, W. J., 3rd, Qiao, Q., Neubert, T. A., Xu, R. M., Gozani, O., and Reinberg, D. (2009) The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J. Biol. Chem. 284, 34283–34295
12. Kuo, A. J., Cheung, P., Chen, K., Zee, B. M., Kioi, M., Lauring, J., Xi, Y., Park, B. H., Shi, X., Garcia, B. A., Li, W., and Gozani, O. (2011) NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 44, 669–620
13. Edmunds, J. W., Mahadevan, L. C., and Clayton, A. L. (2008) Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J. 27, 406–420
14. Albert, M., and Helin, K. (2010) Histone methyltransferases in cancer. Semin. Cell Dev. Biol. 21, 209–220
15. Nimura, K., Ura, K., and Kaneda, Y. (2010) Histone methyltransferases: regulation of transcription and contribution to human disease. J. Mol. Med. 88, 1213–1220
16. Kelly, T. K., De Carvalho, D. D., and Jones, P. A. (2010) Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 28, 1069–1078
17. Huang, S. (1994) Blimp-1 is the murine homolog of the human transcriptional repressor PRDI-BF1. Cell 78, 9
18. Buyse, I. M., Shao, G., and Huang, S. (1995) The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein. Proc. Natl. Acad. Sci. U.S.A. 92, 4467–4471
19. Huang, S., Shao, G., and Liu, L. (1998) The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the
SET domain functioning in chromatin-mediated gene expression. J. Biol. Chem. 273, 15933–15939.

20. Huang, S. (2002) Histone methyltransferases, diet nutrients and tumour suppressors. Nat. Rev. Cancer 2, 469–476.

21. Fumasoni, I., Meani, N., Rambaldi, D., Scafetta, G., Alcalay, M., and Ciccarelli, F. D. (2007) Family expansion and gene rearrangements contributed to the functional specialization of PRDM genes in vertebrates. BMC Evol. Biol. 7, 187.

22. Hohenauer, T., and Moore, A. W. (2012) The Prdm family: expanding roles in stem cells and development. Development 139, 2267–2282.

23. Rea, S., Eisenhaber, F., O’Carroll, D., Strahl, B. D., Sun, Z. W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., and Jenuwein, T. (2000) Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406, 593–599.

24. Kim, K. C., Geng, L., and Huang, S. (2003) Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res. 63, 7619–7623.

25. Derunes, C., Bríkanarová, K., Geng, L., Li, S., Gessner, C. R., Hewitt, K., Wu, S., Huang, S., Woods, V. I., Jr., and Ely, K. R. (2005) Characterization of the PR domain of RIZ1 histone methyltransferase. Biochem. Biophys. Res. Commun. 333, 925–934.

26. Wu, Y., Ferguson, J. E., 3rd, Wang, H., Kelley, R., Ren, R., McDonough, H., Meeker, J., Charles, P. C., Wang, H., and Patterson, C. (2008) PRDM6 is enriched in vascular precursors during development and inhibits endothelial cell proliferation, survival, and differentiation. J. Mol. Cell Cardiol. 44, 47–58.

27. Eom, G. H., Kim, K., Kim, S. M., Lee, H. J., Kim, J. Y., Jin, H. M., Kim, J. R., Kim, J. H., Choe, N., Kim, K. B., Lee, J., Joo, K., Kim, N., and Seo, S. B. (2009) Histone methyltransferase PRDM8 regulates mouse testis steroidogenesis. Biochem. Biophys. Res. Commun. 388, 131–136.

28. Hayashi, K., Yoshida, K., and Matsui, Y. (2005) A histone H3 methyltransferase controls epigenetic events required for meiotic prophase. Nature 438, 374–378.

29. Pinheiro, I., Margueron, R., Shukeir, N., Eisdol, M., Fritzsch, C., Richter, F. M., Mittler, G., Genoud, C., Goyama, S., Kurokawa, M., Son, J., Reineberg, D., Lachner, M., and Jenuwein, T. (2012) Prdm5 and Prdm14 are H3K9me1 methyltransferases required for mammalian heterochromatin integrity. Cell 150, 948–960.

30. Birtle, Z., and Ponting, C. P. (2006) Meisetz and the birth of the KRAB PR domain of RIZ1 histone methyltransferase. Nat. Rev. Genet. 7, 1124–1129.

31. Berg, I. L., Neumann, R., Lam, K. W., Sarbajna, S., Odenthal-Hesse, L., May, C. A., and Jeffreys, A. J. (2010) PRDM9 variation strongly influences the regulation of the H3K4 methyltransferase activity of PRDM9. J. Mol. Biol. 407, 419–430.
56. Kolasinska-Zwierz, P., Down, T., Latorre, I., Liu, T., Liu, X. S., and Ar-ringer, J. (2009) Differential chromatin marking of introns and expressed exons by H3K36me3. Nat. Genet. 41, 376–381
57. Li, F., Mao, G., Tong, D., Huang, J., Gu, L., Yang, W., and Li, G. M. (2013) The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSβ. Cell 153, 590–600
58. Newbold, R. F., and Mokbel, K. (2010) Evidence for a tumour suppressor function of SETD2 in human breast cancer: a new hypothesis. Anticancer Res. 30, 3309–3311
59. Duns, G., van den Berg, E., van Duivenbode, I., Osinga, J., Hollema, H., Hofstra, R. M., and Kok, K. (2010) Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res. 70, 4287–4291
60. Faber, P. W., Barnes, G. T., Srinidhi, J., Chen, J., Gusella, J. F., and MacDonald, M. E. (1998) Huntington interacts with a family of WW domain proteins. Hum. Mol. Genet. 7, 1463–1474
61. Anand, M., and Prasad, B. V. (2012) The computational analysis of human testis transcriptome reveals closer ties to pluripotency. J. Hum. Reprod. Sci. 5, 266–273